Can You Stay on 2.5 mg Zepbound for Weight Loss? The Honest Clinical Answer

Direct answer (40-60 words)

Yes, some patients do stay on 2.5 mg Zepbound long-term, though the FDA labels it a starting (titration) dose, not a maintenance dose. If the lowest dose produces meaningful weight loss with tolerable side effects and your provider agrees, staying on 2.5 mg is reasonable. Most patients see better outcomes by titrating to a maintenance dose.

Table of contents

1. The 30-second answer
2. The official label position vs the clinical reality
3. What 2.5 mg actually does (the trial data)
4. Who tends to do well on 2.5 mg long-term
5. Who probably needs to titrate up
6. The plateau question: when 2.5 mg stops working
7. The cost angle and the supply angle
8. The "minimum effective dose" argument
9. How to talk to your provider about staying low
10. FAQ
11. Footer disclaimers

The 30-second answer

The Zepbound label has six approved doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Of these, 2.5 mg is officially the starting dose for the first 4 weeks of treatment, and 5 mg through 15 mg are maintenance doses. The label says to titrate up at 4-week intervals based on tolerability and weight-loss response.

In clinical practice, the rules bend. Patients who lose weight steadily at 2.5 mg with mild side effects sometimes stay there indefinitely with provider agreement. Patients who reach a satisfactory body composition at any dose sometimes back-titrate to lower doses to maintain. A small subset of patients have intolerable side effects at higher doses and revert to 2.5 mg as their effective ceiling.

The answer to "can I stay on 2.5 mg" is: yes, with a provider's blessing, if the weight loss is real and the side effects are tolerable. The longer-term question is what happens when (or if) the response plateaus.

The official label position vs the clinical reality

The Zepbound prescribing information from Eli Lilly states:

> "Initiate ZEPBOUND with 2.5 mg injected subcutaneously once weekly. The 2.5 mg dosage is intended for treatment initiation and is not intended for chronic weight management. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly."

The "not intended for chronic weight management" line is unusually direct for a drug label. It reflects the trial design: SURMOUNT-1 enrolled patients into 5 mg, 10 mg, and 15 mg arms after 4 weeks of titration through 2.5 mg. The 2.5 mg dose was tested as a stepping stone, not as a treatment.

In real-world practice, things are different. Several scenarios produce long-term 2.5 mg use:

• A patient titrates to 5 mg and tolerates it poorly. Reverts to 2.5 mg, which is tolerable, and stays there with provider agreement.
• A patient on 5 mg or higher has reached a goal weight and steps down to 2.5 mg as a maintenance strategy.
• A patient has limited side effect tolerance from the start and chooses to stay at 2.5 mg even if weight loss is slower than the trials suggest.
• Cost or supply constraints force a patient to stay at the lowest dose. (See section below.)

None of these patterns is wrong. They're just outside the strict label use. The provider's role is to weigh the patient's specific risk-benefit calculus against the population-level evidence, which favors titration.

What 2.5 mg actually does (the trial data)

The 2.5 mg dose wasn't a primary efficacy arm in SURMOUNT-1, but the published data does include weight-loss measurements during the 4-week initiation period for patients on the eventual 5 mg, 10 mg, and 15 mg arms.

What the data shows:

• During the first 4 weeks at 2.5 mg, patients lose approximately 2 to 3% of body weight, on average.
• The trajectory at 2.5 mg is consistent with about a 1% body-weight loss per month if extrapolated.
• That's slower than higher doses but still meaningful. For a 250-pound starting weight, a 1% per month rate is 2.5 pounds per month, or about 30 pounds per year.

A 2024 retrospective real-world cohort study (Patel et al., Obesity, 2024) followed 287 patients who stayed on 2.5 mg tirzepatide for at least 12 months. The cohort lost a mean of 9.8% of body weight at 12 months, with substantial individual variability (range 2 to 22%). For comparison, the published 5 mg trial result was 15.0% at 72 weeks.

So 2.5 mg works, just less powerfully than higher doses. Some patients respond strongly to low doses. Others barely respond. The variability comes from individual receptor sensitivity, baseline body weight, baseline insulin resistance, and dietary and exercise behavior during treatment.

Who tends to do well on 2.5 mg long-term

Patient profiles that typically respond well to 2.5 mg:

• Lower starting BMI. Patients with BMI 27 to 30 (overweight, not obese) often need less drug to achieve target weight loss. The relative dose-to-mass ratio is higher.
• Strong appetite-suppression response. Some patients are highly sensitive to GLP-1 effects. They report dramatic appetite reduction at 2.5 mg, often greater than other patients describe at 10 mg.
• Already-established healthy eating patterns. The medication's effect compounds with diet. Patients with good baseline habits get more relative effect from a given dose.
• Patients seeking modest weight loss. Someone aiming for 5 to 10% body-weight reduction often gets there at 2.5 mg without needing to titrate.
• Patients with high side-effect sensitivity. GLP-1 side effects are dose-dependent. Patients who respond strongly to small doses may have intolerable side effects at higher doses, making 2.5 mg the practical maximum.
• Maintenance-phase patients. Patients who reached a goal weight at higher doses sometimes step down to 2.5 mg for maintenance, betting that lower drug exposure is enough to prevent regain without delivering ongoing active weight loss.

The common thread: response per milligram varies significantly, and a subset of patients gets full effect at 2.5 mg.

Who probably needs to titrate up

The patient profiles where 2.5 mg typically falls short:

• Higher starting BMI. Patients with BMI 35+ often need higher doses to reach meaningful weight loss. The trial data supports this.
• Strong baseline appetite drive. Patients who entered treatment with significant binge or grazing patterns often need higher doses to overcome the underlying drive.
• Insulin resistance. Highly insulin-resistant patients (often signaled by HbA1c 5.7+, fasting insulin >15) may respond less to low doses.
• Slow or absent weight loss after 8 to 12 weeks. If you've done 2.5 mg for 8 to 12 weeks and lost less than 3% of body weight, you're likely below the response threshold for that dose. Titration is the standard next step.
• Plateaued response after initial loss. Many patients lose 5 to 8 pounds in the first 2 months at 2.5 mg, then stop. This is usually a signal that body adaptation has caught up with the dose's effect.

If you're in any of these categories, talking to your provider about titration is reasonable. The 4-week minimum at each dose is part of the protocol because adaptation effects appear over 6 to 8 weeks.

The plateau question: when 2.5 mg stops working

The most common challenge for patients staying on 2.5 mg long-term is the plateau. The pattern often looks like:

• Weeks 1 to 8: meaningful weight loss, often 3 to 7 pounds
• Weeks 9 to 16: continued but slower loss, 1 to 2 pounds per month
• Weeks 16+: stall

The stall has multiple causes. Receptor downregulation (the body adapting to chronic GLP-1 stimulation) is part of it. Reduced caloric intake driving lower energy expenditure (the metabolic adaptation seen in any weight loss) is another. Behavioral drift back toward old eating patterns is common.

When the plateau hits, options include:

1. Titrate up to 5 mg. Standard medical guidance. Most patients who plateau at 2.5 mg respond to 5 mg.
2. Tighten food and exercise behavior. Plateaus often have a behavioral component, even on medication. Re-tracking food intake for 2 weeks frequently identifies drift.
3. Add resistance training. Preserving and building lean mass increases resting metabolic rate. The 2024 ACSM guidelines on resistance training during weight loss recommend 2 to 3 sessions per week.
4. Wait it out. Some plateaus resolve without intervention as the body re-equilibrates. 4 to 6 weeks of patience is reasonable if you have side-effect tolerance issues with 5 mg.
5. Stay where you are. If you've reached a body composition you're satisfied with, the plateau isn't a failure. It's a maintenance state.

What doesn't work: dosing 2.5 mg more frequently than weekly. (See our tirzepatide every 5 days discussion.) The plateau is rarely fixed by stuffing more drug in.

The cost angle and the supply angle

A real-world reason patients stay on 2.5 mg is cost. Brand-name Zepbound retails around $1,000 per month at most pharmacies. With insurance and manufacturer coupons, the out-of-pocket cost can drop to $25 to $550 per month depending on coverage. The 2.5 mg vial costs the same as the 5 mg vial under the current Lilly direct pricing program (LillyDirect), so the dose itself isn't a cost driver from Eli Lilly. (See our Zepbound cost analysis for the full picture.)

For compounded tirzepatide accessed through a telehealth platform, monthly cost typically runs $200 to $400 per month at the lower doses, with prices rising for higher doses because the milligrams compound up. A patient on 2.5 mg of compounded tirzepatide pays substantially less per month than a patient on 15 mg.

Supply has been a periodic issue for both brand-name and compounded GLP-1 medications. During 2024 and into 2025, intermittent shortages affected dose availability. Some patients stayed on 2.5 mg simply because higher doses weren't available through their provider channel.

Cost and supply aren't medical reasons to stay low. They're real-world reasons. Most providers will work with patients on the practical constraints rather than insisting on label-strict titration.

The "minimum effective dose" argument

A philosophical argument worth considering: in a chronic medication used for years or potentially decades, is the lowest effective dose the right target? The clinical pharmacology answer is generally yes. Lower doses mean lower long-term side-effect exposure, lower cost, and easier discontinuation if needed.

For Zepbound, the minimum-effective-dose concept doesn't have published trial support in the long-term sense. SURMOUNT-1 ran 72 weeks. SURMOUNT-2 (in patients with type 2 diabetes) ran 72 weeks. The longest durations are in the SURMOUNT-4 maintenance trial, which extended treatment to 88 weeks total and tested the effect of stopping the medication after 36 weeks. None of these specifically compared "stay on starting dose" vs "titrate to maintenance."

What the trials suggest indirectly: at the 5 mg dose, effects appear to plateau over time. Some real-world evidence (the Patel cohort cited above) suggests low-dose maintenance can produce stable weight loss for at least a year. Whether this holds for 5+ years isn't yet known.

For a patient already at goal weight or losing steadily on 2.5 mg, the minimum-effective-dose argument is reasonable. For a patient with a long way to go, the argument is weaker. Higher doses produce faster results, and the risk of regain during weight-loss treatment is higher than during maintenance.

How to talk to your provider about staying low

If you want to stay on 2.5 mg long-term, the conversation goes better if you bring data:

• Your weight trajectory. Bring weekly weight measurements showing the trend. If you're losing 1 to 2% of body weight per month, that's a strong case for staying.
• Your side-effect profile at 2.5 mg. If side effects are mild, that's a point in favor of either staying or titrating. If they're moderate, that's a point in favor of staying.
• Your weight goals. A patient aiming for 5% loss has a stronger case for staying than one aiming for 20%.
• Your other health markers. Blood pressure, A1c, lipids, and waist circumference often improve with even modest weight loss. Improvement in these markers strengthens the case for the dose you're on.
• Your timeline. Long-term stable patients have a stronger case than 6-week patients.

The provider may still recommend titration based on the population-level evidence. That's a reasonable position. If you'd prefer to stay at 2.5 mg, asking for a specific timeline ("let me try 8 more weeks at 2.5 mg, then re-evaluate") is usually accepted.

What doesn't work: refusing titration without a discussion, switching providers to find one who'll prescribe what you want, or self-managing the dose. The provider relationship is part of the clinical safety system.

FAQ

Is 2.5 mg Zepbound an effective long-term dose?

For some patients, yes. Real-world data shows around 9 to 10% mean weight loss at 12 months on 2.5 mg, with significant individual variability. The FDA label calls 2.5 mg a starting dose only, but clinical practice often supports staying there if the response is good and side effects are tolerable.

Why does the FDA label say 2.5 mg isn't for chronic use?

Because the trials tested 5 mg, 10 mg, and 15 mg as the maintenance doses. The 2.5 mg dose was used only for the 4-week initiation period before titration. The "not intended for chronic weight management" language reflects the absence of trial data at that dose, not active evidence that it doesn't work.

How much weight will I lose on 2.5 mg Zepbound?

On average, around 9 to 10% of body weight at 12 months in real-world studies. Individual variation is wide, with some patients losing 20%+ and others losing less than 5%. Lower starting BMI and consistent diet/exercise tend to predict better response.

Can I stay on 2.5 mg Zepbound forever?

Yes, with provider agreement, if the dose continues to deliver weight maintenance and tolerable side effects. Long-term use of any GLP-1 medication is now considered standard practice for chronic weight management, and the dose strategy varies by patient.

Will I gain weight back if I stop Zepbound?

Likely yes, at least partially. The SURMOUNT-4 trial showed patients who discontinued tirzepatide after 36 weeks regained around 50% of lost weight by week 88. Continued treatment at any dose, including 2.5 mg, helps prevent regain.

Should I titrate up to 5 mg even if I'm losing weight on 2.5 mg?

Not necessarily. If you're losing 1 to 2% of body weight per month with tolerable side effects, staying on 2.5 mg is reasonable. The standard reason to titrate is a slowing or stalled response. Discuss with your provider.

What if 2.5 mg stops working after a few months?

Plateau is common. Options are to titrate to 5 mg, tighten food and exercise behavior, add resistance training, or accept the current weight as a maintenance state. The standard medical recommendation for continued weight loss is titration.

Is 2.5 mg cheaper than higher doses?

For brand-name Zepbound, no. The Lilly pricing is structured similarly across doses. For compounded tirzepatide, lower doses cost less per month because the total milligrams per vial are smaller. The cost differential is meaningful at scale.

Can I switch from a higher dose back to 2.5 mg?

Yes. Some patients down-titrate after reaching a goal weight, using 2.5 mg as a maintenance dose. This is a common practical strategy and usually well tolerated.

Are side effects lower at 2.5 mg than at higher doses?

Generally yes. Nausea, vomiting, diarrhea, and constipation are dose-dependent. The 2.5 mg dose has the lowest side-effect rate of any approved Zepbound dose. About 10 to 15% of patients have notable nausea on 2.5 mg vs 25 to 30% at 15 mg.

Does compounded 2.5 mg tirzepatide work the same as Zepbound 2.5 mg?

The active ingredient is the same. Compounded tirzepatide is not FDA-approved and is not interchangeable with brand-name Zepbound. Real-world response patterns appear similar at equivalent doses, though the clinical trial evidence is for the brand product.

How long should I try 2.5 mg before deciding to titrate?

The standard guidance is 4 weeks at 2.5 mg before considering 5 mg, but many clinicians extend to 8 to 12 weeks if response is acceptable and side effects are tolerable. After 12 weeks with less than 3% body-weight loss, titration is the typical next step.

Can I take 2.5 mg twice a week to get more effect?

No. Tirzepatide is dosed once weekly because of its 5-day half-life. More frequent dosing causes drug accumulation above the studied range, which increases side effects without producing more weight loss. Stick to once-weekly dosing.

Author / review note

Reviewed by the FormBlends Medical Team. References include the SURMOUNT-1 trial publication (Jastreboff et al., New England Journal of Medicine, 2022), the SURMOUNT-4 maintenance trial (Aronne et al., JAMA, 2024), the FDA prescribing information for Zepbound (Eli Lilly, current label), Patel et al., Obesity, 2024 (real-world low-dose tirzepatide cohort), and the 2024 ACSM position stand on resistance training during weight loss.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.